晚期卵巢癌病理完全缓解者的临床分析
本回顾性研究纳入两个接受新辅助化疗后行间歇性肿瘤减灭术的患者群体:单中心472例及病理完全缓解(pCR)患者67例(含单中心23例及协作机构44例)。pCR患者中位无复发生存期(RFS)24.2个月、总生存期(OS)80.8个月,中位随访32.4个月;单中心pCR率4.9%,pCR者RFS和OS均长于残留病灶者;手术时CA125正常者获pCR的OR为3.54(95%CI 1.14-11.05,p=0.029)。
要点
- pCR患者中位RFS 24.2个月、OS 80.8个月,中位随访32.4个月。
- 单中心pCR率4.9%,pCR者RFS长于显微镜下、最佳或次佳残留病灶者。
- 手术时CA125正常者获pCR的OR 3.54(95%CI 1.14-11.05,p=0.029)。
核心结论
- 新辅助化疗后获pCR的晚期卵巢癌女性,在间歇性肿瘤减灭术时相比有残留存活肿瘤者RFS显著更长;CA125可能是术前识别这些极端应答者的可行生物标志物。
研究设计与样本
- 回顾性研究,使用两个接受新辅助化疗后行间歇性肿瘤减灭术的患者群体:第一个为单中心472例,第二个仅含pCR患者67例(来自第一个群体者加协作机构44例)。
- 采用Cox分析和log-rank检验评估临床特征与pCR结局、无复发生存期(RFS)和总生存期(OS)的关联。
主要发现
- pCR-only群体中位RFS 24.2个月、OS 80.8个月,中位随访32.4个月。
- 单中心群体中23例(4.9%)达pCR,其RFS长于非pCR的显微镜下残留、最佳残留、次佳残留者(24.3 vs. 12.1 vs. 11.6 vs. 9.6个月,p分别=0.025、0.012、0.008)。
- pCR者OS长于最佳残留和次佳残留者(54.5 vs. 29.4 vs. 25.7个月,p分别=0.027、0.007)。
- 手术时CA125正常者获pCR的可能性超过三倍(OR 3.54,95%CI 1.14-11.05,p=0.029)。
关键数值与推荐
- 单中心群体472例中23例(4.9%)达pCR。
- pCR-only群体67例中位RFS 24.2个月、OS 80.8个月,中位随访32.4个月。
- 手术时CA125正常者获pCR的OR 3.54(95%CI 1.14-11.05,p=0.029)。
临床怎么用
- 作者认为CA125可能是术前识别新辅助化疗后pCR极端应答者的可行生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the clinical characteristics of patients who attained pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) and to identify specific predictive or prognostic factors associated with pCR. METHODS: Two distinct populations of patients who underwent NACT followed by interval tumor reductive surgery (TRS) were used in this retrospective study. The first contained 472 patients from a single institution. The second contained only pCR patients (67); those identified from population one, plus 44 obtained through collaborative institutions. Cox analysis and log-rank tests were performed to assess associations between clinical characteristics and pCR outcome, recurrence-free survival (RFS), and overall survival (OS). RESULTS: The median RFS and OS in our pCR-only population was 24.2 and 80.8 months, respectively, with a median follow-up time of 32.4 months. In our single institution population, 23 patients attained pCR (4.9%) and had longer RFS compared to non-pCR patients with viable microscopic, optimal, or suboptimal residual disease (24.3 vs. 12.1 vs. 11.6 vs. 9.6 months, p = 0.025, 0.012, 0.008, respectively), and longer OS compared to those with optimal or suboptimal residual disease (54.5 vs. 29.4 vs. 25.7 months, p = 0.027, 0.007, respectively). Patients were more than three-fold likely to attain pCR if their CA125 value was normal at the time of surgery (OR 3.54, 95% CI: 1.14-11.05, p = 0.029). CONCLUSIONS: Women with pCR after NACT have significantly longer RFS compared to those with residual viable tumor at the time of interval tumor-reductive surgery, and CA125 is plausible biomarker for identifying these extreme responders preoperatively.
引用
- LaFargue CJ, Handley KF, Fleming ND, et al. Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. Gynecol Oncol. 2022. PMID: 35216808. doi:10.1016/j.ygyno.2022.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。